19 February 2025

---

Remora Appoints Martin Laudenbach as Chair to Lead Sustainable Growth

---

Remora, an award-winning leader in sustainable biofilm prevention technology, has announced the appointment of international business expert Martin Laudenbach as an independent director and its next Chair.

The appointment marks a significant milestone in Remora’s journey toward revolutionizing biofilm prevention across various sectors, including healthcare, paints and coatings, and textiles.

Developed in Scotland, the cutting-edge Remora technology is inspired by the natural behavior of red seaweed and backed by a decade-long collaboration with Unilever, along with support from leading UK universities and research bodies. The patented technology is a sustainable and non-toxic alternative to conventional antibacterial agents.

Martin Laudenbach has a proven track record of leading international businesses to success and brings a wealth of business and market expertise from a career spanning more than 30 years. He has held senior international leadership roles in organizations within the chemical industry, including BASF and Solvay, with his roles spanning Europe, the US, and Asia.

Currently based in Frankfurt, Martin advises investors, boards, and C-level executives on transforming their businesses for superior performance and sustained profitable growth. His deep understanding of market forces, business models, and value drivers, combined with his ability to navigate disruptive changes, has led to substantial improvements in business performance—something he seeks to bring to his role with Remora.

“I am passionate about working with organizations that take inspiration from nature and have a real vision for sustainable growth,” said Martin Laudenbach, Chair at Remora. “The Remora technology offers a truly game-changing solution to harmful biofilms, and I am excited to join the team and share my experience in guiding businesses to achieve commercial success. Remora has a talented team with a shared belief in what they are working to achieve. I’m looking forward to working with them on their growth journey.”

“Martin’s strategic vision and passion for innovation and sustainability will be instrumental in guiding Remora through its next phase of growth and development,” said Dr. Richard Hammond, CEO of Remora, welcoming Martin’s appointment. “His impressive track record and dedication to sustainable practices align perfectly with our values and mission. Martin’s advice and strategic guidance will be invaluable as we continue to innovate and expand our unique biofilm prevention technology for a wide range of applications and sectors, providing safer and more sustainable solutions for our clients.”

About Remora

Remora has created a unique and sustainable biotechnology solution to harmful biofilms.

Remora is an award-winning biofilm prevention technology inspired by the natural behavior of red seaweed. Using a scientifically created molecule, Remora can effectively and sustainably prevent the formation of harmful biofilms.

Created following a decade-long collaboration with Unilever, as well as wider support from a range of UK universities and research bodies, this patented technology blocks biofilm formation in a wide range of applications, including textiles, paints and coatings, and healthcare settings.

Remora can be effectively used in combination with other chemicals and offers a sustainable, non-toxic alternative to conventional antibacterial agents, promoting cleaner, safer, and more durable environments.

Impact of Biofilms

Biofilms are structured communities of microbes encased in a self-produced protective layer, capable of attaching to various surfaces. These resilient communities pose significant challenges across multiple sectors, including healthcare, the built environment, and textiles. Harmful biofilms can lead to increased bacterial infections in humans and animals, accelerated degradation of materials like steel and concrete, and persistent contamination issues that complicate cleaning and maintenance efforts.

Over 80% of bacterial infections in humans involve biofilm formation, exacerbating the global issue of antimicrobial resistance (AMR). Standard antibiotics and disinfectants often fail against biofilms due to their protective matrix and coordinated microbial behavior.